Omeros CorpNASDAQ:OMER
- LAST PRICE3.4500
- TODAY'S CHANGE (%)0.1400 (4.2296%)
- Bid / Lots3.3000/ 1
- Ask / Lots3.4300/ 1
- Open / Previous Close3.3000 / 3.3100
- Day Range
- 52 Week Range
- Volume374,899
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 35639 | 3.285 |
| 09:34 ET | 3240 | 3.2894 |
| 09:36 ET | 8511 | 3.28 |
| 09:38 ET | 839 | 3.285 |
| 09:39 ET | 6122 | 3.37 |
| 09:41 ET | 3374 | 3.412 |
| 09:43 ET | 3718 | 3.4201 |
| 09:45 ET | 5862 | 3.42 |
| 09:48 ET | 1491 | 3.43 |
| 09:50 ET | 2227 | 3.43 |
| 09:52 ET | 5240 | 3.47 |
| 09:54 ET | 300 | 3.48 |
| 09:56 ET | 1473 | 3.482 |
| 09:57 ET | 13677 | 3.54 |
| 09:59 ET | 2933 | 3.525 |
| 10:01 ET | 3529 | 3.52 |
| 10:03 ET | 2038 | 3.53 |
| 10:06 ET | 1944 | 3.539 |
| 10:08 ET | 200 | 3.52 |
| 10:12 ET | 8013 | 3.45 |
| 10:14 ET | 3093 | 3.47 |
| 10:15 ET | 4297 | 3.435 |
| 10:17 ET | 563 | 3.44 |
| 10:19 ET | 100 | 3.445 |
| 10:21 ET | 706 | 3.45 |
| 10:26 ET | 3000 | 3.4401 |
| 10:30 ET | 1300 | 3.415 |
| 10:32 ET | 100 | 3.42 |
| 10:33 ET | 4100 | 3.405 |
| 10:35 ET | 200 | 3.405 |
| 10:37 ET | 3055 | 3.42 |
| 10:39 ET | 18287 | 3.435 |
| 10:44 ET | 5509 | 3.4 |
| 10:46 ET | 100 | 3.395 |
| 10:48 ET | 1130 | 3.3901 |
| 10:51 ET | 279 | 3.39 |
| 11:00 ET | 200 | 3.38 |
| 11:02 ET | 141 | 3.38 |
| 11:09 ET | 100 | 3.385 |
| 11:11 ET | 500 | 3.3801 |
| 11:13 ET | 4441 | 3.35 |
| 11:15 ET | 4854 | 3.38 |
| 11:24 ET | 531 | 3.36 |
| 11:26 ET | 700 | 3.34 |
| 11:27 ET | 191 | 3.34 |
| 11:29 ET | 299 | 3.3399 |
| 11:31 ET | 646 | 3.31 |
| 11:33 ET | 1000 | 3.3001 |
| 11:40 ET | 15180 | 3.32 |
| 11:42 ET | 1600 | 3.3 |
| 11:44 ET | 1148 | 3.31 |
| 11:47 ET | 900 | 3.3085 |
| 11:51 ET | 300 | 3.305 |
| 11:54 ET | 300 | 3.2999 |
| 11:56 ET | 1000 | 3.3 |
| 12:02 ET | 371 | 3.3 |
| 12:07 ET | 2418 | 3.3 |
| 12:09 ET | 200 | 3.3059 |
| 12:14 ET | 2556 | 3.33 |
| 12:18 ET | 175 | 3.339 |
| 12:20 ET | 200 | 3.3309 |
| 12:21 ET | 2242 | 3.35 |
| 12:23 ET | 398 | 3.345 |
| 12:25 ET | 100 | 3.35 |
| 12:32 ET | 142 | 3.36 |
| 12:36 ET | 398 | 3.365 |
| 12:38 ET | 300 | 3.3629 |
| 12:39 ET | 3231 | 3.355 |
| 12:43 ET | 500 | 3.335 |
| 12:45 ET | 1705 | 3.33 |
| 12:48 ET | 339 | 3.31 |
| 12:50 ET | 773 | 3.305 |
| 12:52 ET | 665 | 3.31 |
| 12:54 ET | 400 | 3.3044 |
| 12:56 ET | 200 | 3.31 |
| 12:59 ET | 3100 | 3.305 |
| 01:10 ET | 143 | 3.305 |
| 01:12 ET | 3150 | 3.3 |
| 01:14 ET | 350 | 3.295 |
| 01:15 ET | 3165 | 3.325 |
| 01:21 ET | 1434 | 3.35 |
| 01:24 ET | 200 | 3.35 |
| 01:33 ET | 100 | 3.355 |
| 01:37 ET | 700 | 3.36 |
| 01:42 ET | 500 | 3.355 |
| 01:44 ET | 161 | 3.3501 |
| 01:48 ET | 100 | 3.355 |
| 02:02 ET | 100 | 3.35 |
| 02:04 ET | 1000 | 3.345 |
| 02:06 ET | 100 | 3.3412 |
| 02:11 ET | 1716 | 3.34 |
| 02:13 ET | 1842 | 3.34 |
| 02:18 ET | 100 | 3.355 |
| 02:20 ET | 222 | 3.35 |
| 02:22 ET | 227 | 3.35 |
| 02:24 ET | 400 | 3.335 |
| 02:26 ET | 1400 | 3.335 |
| 02:27 ET | 1577 | 3.34 |
| 02:36 ET | 600 | 3.345 |
| 02:38 ET | 600 | 3.345 |
| 02:40 ET | 100 | 3.345 |
| 02:42 ET | 200 | 3.345 |
| 02:47 ET | 100 | 3.345 |
| 02:49 ET | 219 | 3.345 |
| 02:51 ET | 300 | 3.345 |
| 02:54 ET | 4127 | 3.3401 |
| 02:56 ET | 1030 | 3.345 |
| 02:58 ET | 700 | 3.345 |
| 03:00 ET | 100 | 3.345 |
| 03:02 ET | 2280 | 3.335 |
| 03:03 ET | 4132 | 3.34 |
| 03:05 ET | 741 | 3.345 |
| 03:16 ET | 7074 | 3.38 |
| 03:18 ET | 400 | 3.375 |
| 03:20 ET | 500 | 3.375 |
| 03:21 ET | 2990 | 3.4 |
| 03:23 ET | 1301 | 3.395 |
| 03:25 ET | 100 | 3.395 |
| 03:27 ET | 1100 | 3.395 |
| 03:30 ET | 758 | 3.395 |
| 03:32 ET | 300 | 3.395 |
| 03:34 ET | 6559 | 3.425 |
| 03:36 ET | 655 | 3.4232 |
| 03:38 ET | 100 | 3.425 |
| 03:39 ET | 926 | 3.425 |
| 03:41 ET | 233 | 3.425 |
| 03:43 ET | 2860 | 3.415 |
| 03:45 ET | 1300 | 3.405 |
| 03:48 ET | 1891 | 3.405 |
| 03:50 ET | 2006 | 3.41 |
| 03:52 ET | 2535 | 3.425 |
| 03:54 ET | 5462 | 3.45 |
| 03:56 ET | 4041 | 3.45 |
| 03:57 ET | 5790 | 3.445 |
| 03:59 ET | 5093 | 3.45 |
May 16, 2024
DJ Omeros Shares Drop 20% After Wider 1Q Loss, from 10:57AM ET on Thursday May 16, 2024 by Dow Jones
10:57AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
*DJ Omeros 1Q Loss/Shr 63c >OMER, from 4:02PM ET on Wednesday May 15, 2024 by Dow Jones
4:02PM ET on Wednesday May 15, 2024 by Dow JonesOmeros Corporation Reports First Quarter 2024 Financial Results, from 4:02PM ET on Wednesday May 15, 2024 by Dow Jones
4:02PM ET on Wednesday May 15, 2024 by Dow Jones
May 10, 2024
Press Release: Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024, from 8:50AM ET on Friday May 10, 2024 by Dow Jones
8:50AM ET on Friday May 10, 2024 by Dow JonesOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024, from 8:50AM ET on Friday May 10, 2024 by Dow Jones
8:50AM ET on Friday May 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 199.9M | -1.2x | --- |
Galectin Therapeutics Inc | 199.9M | -4.4x | --- |
Cytodyn Inc | 198.7M | -3.6x | --- |
Elevation Oncology Inc | 197.2M | -3.5x | --- |
Atossa Therapeutics Inc | 196.7M | -6.7x | --- |
Trevi Therapeutics Inc | 195.1M | -8.2x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Vice President - Finance, Chief Accounting Officer, Treasurer
- Michael Jacobsen
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
- Vice President - Human Resources
- Peter Williams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $199.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.36 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
